Detection of tumor-associated antigens in culture supernatants using autoantibodies in sera from patients with bladder cancer

Biomedical Research (Japan)

Volumn 35, Issue 1, 2014, Pages 25-35

  Minami, Sho ^a   Nagashio, Ryo ^a   Ueda, Junpei ^a   Matsumoto, Kazumasa ^a   Goshima, Naoki ^b   Hattori, Manabu ^a   Hachimura, Kazuo ^a   Iwamura, Masatsugu ^a   Sato, Yuichi ^a  

^a KITASATO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CALRETICULIN ANTIBODY; CANCER ANTIBODY; GELATINASE A; GELATINASE A ANTIBODY; IMMUNOGLOBULIN G; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER SURVIVAL; CENTRIFUGATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; TWO DIMENSIONAL GEL ELECTROPHORESIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AUTOANTIBODIES; CALRETICULIN; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84896840441     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.35.25     Document Type: Article

References (50)

1. Bas WG van Rhijn, Henk G van der Poel, Theo H van der Kwast (2009) Cytology and urinary markers for the diagnosis of bladder cancer. Eur Urol Suppl 8, 536-541.
2. Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini V, Hochstrasser DF and Tosi P (1997) Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18, 2832-2841.
3. Borden LS Jr, Clark PE and Hall MC (2003) Bladder cancer. Curr Opin Oncol 15, 227-233.
4. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S and Tainsky MA (2006) Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 66, 1181-1190.
5. Chen CN, Chang CC, Su TE, Hsu WM, Jeng YM, Ho MC, Hsieh FJ, Lee PH, Kuo ML, Lee H and Chang KJ (2009) Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol 16, 524-533.
6. Diamandis EP (2004) How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. Clin Chem 50, 793-795.
7. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R and Cheever MA (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54, 16-20.
8. Coppolino MG, Woodside MJ, Demaurex N, Grinstein S, St Arnaud R and Dedhar S (1997) Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 386, 843-847.
9. Du XL, Hu H, Lin DC, Xia SH, Shen XM, Zhang Y, Luo ML, Feng YB, Cai Y, Xu X, Han YL, Zhan QM and Wang MR (2007) Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J Mol Med (Berl) 85, 863-875.
10. Erić-Nikolić A, Milovanović Z, Sánchez D, Pekáriková A, Džodić R, Matić IZ, Tučková L, Jevrić M, Buta M, Rašković S and Juranić Z (2012) Overexpression of calreticulin in malignant and benign breast tumors: relationship with humoral immunity. Oncology 82, 48-55.
11. Fernández Madrid F (2005) Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett 18, 187-198.
12. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, Micela M, Stetler-Stevenson WG and Liotta LA (1992) Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52, 4548-4549.
13. Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D and Loening SA (2001) Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57, 675-679.
14. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S and Nakajima M (1996) Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78, 2379-2387.
15. Goshima N, Kawamura Y, Fukumoto A, Miura A, Honma R, Satoh R, Wakamatsu A, Yamamoto J, Kimura K, Nishikawa T, Andoh T, Iida Y, Ishikawa K, Ito E, Kagawa N, Kaminaga C, Kanehori K, Kawakami B, Kenmochi K, Kimura R, Kobayashi M, Kuroita T, Kuwayama H, Maruyama Y, Matsuo K, Minami K, Mitsubori M, Mori M, Morishita R, Murase A, Nishikawa A, Nishikawa S, Okamoto T, Sakagami N, Sakamoto Y, Sasaki Y, Seki T, Sono S, Sugiyama A, Sumiya T, Takayama T, Takayama Y, Takeda H, Togashi T, Yahata K, Yamada H, Yanagisawa Y, Endo Y, Imamoto F, Kisu Y, Tanaka S, Isogai T, Imai J, Watanabe S and Nomura N (2008) Human protein factory for converting the transcriptome into an in vitro-expressed proteome. Nat Methods 5, 1011-1017.
16. Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M and Miroglu C (2004) Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 11, 1070-1077.
17. Hanash S (2003) Harnessing immunity for cancer marker discovery. Nat Biotechnol 21, 37-38.
18. Hayashi E, Kuramitsu Y, Okada F, Fujimoto M, Zhang X, Kobayashi M, Iizuka N, Ueyama Y and Nakamura K (2005) Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 5, 1024-1032.
19. Heo CK, Bahk YY and Cho EW (2012) Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Rep 45, 677-685.
20. Kageyama S, Isono T, Matsuda S, Ushio Y, Satomura S, Terai A, Arai Y, Kawakita M, Okada Y and Yoshiki T (2009) Urinary calreticulin in the diagnosis of bladder urothelial carcinoma. Int J Urol 16, 481-486.
21. Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y and Yoshiki T (2004) Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 50, 857-866.
22. Kakehi Y, Hirao Y, Kim WJ, Ozono S, Masumori N, Miyanaga N, Nasu Y and Yokomizo A (2010) Bladder Cancer Working Group report. Jpn J Clin Oncol 40, 57-64.
23. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M and Weider (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66, 4-34.
24. Kobold S, Luetkens T, Cao Y, Bokemeyer C and Atanackovic D (2010) Prognostic and diagnostic value of spontaneous tumor- related antibodies. Clin Dev Immunol 2010, 7215-7231
25. Kulasingam V and Diamandis EP (2007) Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics 6, 1997-2011.
26. Liu R, Gong J, Chen J, Li Q, Song C, Zhang J, Li Y, Liu Z, Dong Y, Chen L and Jin B (2012) Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother 61, 855-864.
27. Lou X, Xiao T, Zhao K, Wang H, Zheng H, Lin D, Lu Y, Gao Y, Cheng S, Liu S and Xu N (2007) Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung cancer. J Proteome Res 6, 1083-1092.
28. Lu YC, Chen CN, Wang B, Hsu WM, Chen ST, Chang KJ, Chang CC and Lee H (2011) Changes in tumor growth and metastatic capacities of J82 human bladder cancer cells suppressed by down-regulation of calreticulin expression. Am J Pathol 179, 1425-1433.
29. Monig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, Thiele J, Dienes HP and Hölscher AH (2001) Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 39, 597-602.
30. Nagashio R, Sato Y, Jiang SX, Ryuge S, Kodera Y, Maeda T and Nakajima T (2008) Detection of tumor-specific autoantibodies in sera of patients with lung cancer. Lung Cancer 62, 364-373.
31. Nanney LB, Woodrell CD, Greives MR, Cardwell NL, Pollins AC, Bancroft TA, Chesser A, Michalak M, Rahman M, Siebert JW and Gold LI (2008) Calreticulin enhances porcine wound repair by diverse biological effects. Am J Pathol 173, 610-630.
32. Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH and Ho DM (2010) Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer- specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol 133, 788-795.
33. Pavlou MP and Diamandis EP (2010) The cancer cell secretome: a good source for discovering biomarkers? J Proteomics 10, 1896-1906.
34. Pekáriková A, Sánchez D, Palová-Jelínková L, Simsová M, Benes Z, Hoffmanová I, Drastich P, Janatková I, Mothes T, Tlaskalová-Hogenová H and Tucková L (2010) Calreticulin is a B cell molecular target in some gastrointestinal malignancies. Clin Exp Immunol 160, 215-222.
35. Roy R, Yang J and Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27, 5287-5297.
36. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Türeci O, Sahin U, Pfreundschuh M and Old LJ (1998) Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 76, 652-658.
37. Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W and Lengyel E (2001) Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7, 2396-2404.
38. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB and Verspaget HW (1996) Tissue levels of matrix metalloproteinases MMP- 2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74, 413-417.
39. Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J and Somiari RI (2006) Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 20, 98-107.
40. Stastna M and Van Eyk JE (2012) Secreted proteins as a fundamental source for biomarker discovery. Proteomics 12, 722-735.
41. Szarvas T, vom Dorp F, Ergün S and Rübben H (2011) Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev Urol 8, 241-254.
42. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, Shariat SF and Zlotta AR (2011) Urine markers for detection and surveillance of nonmuscle- invasive bladder cancer. Eur Urol 60, 484-492.
43. Vasala K, Pääkkö P and Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 62, 952-957.
44. Volpe A, Racioppi M, D'Agostino D, Cappa E, Gardi M, Totaro A, Pinto F, Sacco E, Marangi F, Palermo G and Bassi PF (2008) Bladder tumor markers: a review of the literature. Int J Biol Markers 23, 249-261.
45. Vougas K, Gaitanarou E, Marinos E, Kittas C and Voloudakis- Baltatzis IE (2008) Two-dimensional electrophoresis and immunohistochemical study of calreticulin in colorectal adenocarcinoma and mirror biopsies. J BUON 13, 101-107.
46. Witjes JA and Hendricksen K (2008) Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 53, 45-52.
47. Wu CC, Chen HC, Chen SJ, Liu HP, Hsieh YY, Yu CJ, Tang R, Hsieh LL, Yu JS and Chang YS (2008) Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 8, 316-332.
48. Xue H, Lu B and Lai M (2008) The cancer secretome: a reservoir of biomarkers. J Transl Med 17, 52.
49. Yoon GS, Lee H, Jung Y, Yu E, Moon HB, Song K and Lee I (2000) Nuclear matrix of calreticulin in hepatocellular carcinoma. Cancer Res 60, 1117-1120.
50. Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ and Hirschowitz EA (2004) Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics 4, 1216-1225.